Focus on negatively regulated NLRs in inflammation and cancer

作者：Jian Wang, Wenjing He, Chunhua Li, Yue Ma, Mingjun Liu, Jinxiang Ye, Lei Sun, Jing Su, Lei Zhou · 发表于：International Immunopharmacology · 年份：2024 · DOI：10.1016/j.intimp.2024.112347 · 被引用次数：10 · 研究领域：Inflammasome and immune disorders、Immune Cell Function and Interaction、interferon and immune responses

Nucleotide-binding and oligomerization structural domain (NOD)-like receptors (NLRs) play an important role in innate immunity as cytoplasmic pattern recognition receptors (PRRs). Over the past decade, considerable progress has been made in understanding the mechanisms by which NLR family members regulate immune system function, particularly the formation of inflammasome and downstream inflammatory signals. However, recent studies have shown that some members of the NLRs, including Nlrp12, NLRX1, and NLRC3, are important in the negative regulation of inflammatory signaling and are involved in the development of various diseases, including inflammatory diseases and cancer. Based on this, in this review, we first summarize the interactions between canonical and non-canonical nuclear factor-κB (NF-κB) signaling pathways that are mainly involved in NLRs, then highlight the mechanisms by which the above NLRs negatively regulate inflammatory signaling responses as well as their roles in tumor progression, and finally summarize the synthetic and natural derivatives with therapeutic effects on these NLRs, which are considered as potential therapeutic agents for overcoming inflammatory diseases.